The CML Content Hub Channel

Well Tolerated in Preliminary Study: Pembrolizumab + TKIs in CML Patients With Persistent Detectible MRD

2:12 | CML Content Hub, Oncology, Oncology / Hematology

Amer Zeidan, MBBS, Yale University, provides an update on the preliminary safety results of an ongoing Phase 2 trial testing the effect of pembrolizumab + TKIs in patients with CML and persistent detectible minimal residual disease. So far, the treatment is generally well tolerated, with further results to follow.

More in CML Content Hub

► 3:04

Combination Therapy Options for Blast Phase CML Treatment

CML Content Hub

Mhairi Copland, MBChB, PhD, University of Glasgow, Glasgow, UK, discusses treatment options for blast phase CML, pointing out that TKI therapy alone with ponatinib has a 3-year survival rate of...

► 1:11

Reducing Dosage to Manage Side Effects of Long-Term TKI Use

CML Content Hub

Mhairi Copland, MBChB, PhD, University of Glasgow, Glasgow, UK, suggests that patients with CML who respond to TKI therapy but experience bothersome side effects affecting quality of life may benefit...

► 06:40

Successful Treatment-Free Remission in Patients With CML After TKI Discontinuation

CML Content Hub

In an interview conducted at the European Hematology Association Congress 2022 in Vienna, Austria, Fadi Haddad, MD, from MD Anderson Cancer Center, Houston, TX, discussed results from a study designed...

► 7:06

Timing Discontinuation of Treatment: Critical to Maximize Chances of Successful TFR

CML Content Hub

Fadi Haddad, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses evidence that continuing treatment to keep patients at MR4 or MR4.5 for at least 5 years leads...